CaroGen Announces the Publication of Its Cancer Immunotherapy CARG-2020 Preclinical Data

Farmington, CT, September 20, 2023 – CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology candidate for solid tumors, has been published in the Journal of Acta Pharmaceutica Sinica B (